{"paper_id": "1b6e9ee648a6ffc0297d06e73d3dea87897764f9", "metadata": {"title": "TITLE: Early outcomes of tocilizumab in adults hospitalized with severe COVID-19 - Adri\u00e1n S\u00e1nchez- Adri\u00e1n S\u00e1nchez-Montalv\u00e1 Infectious Diseases Department, Tropical Diseases and Global Health Unit, Vall d'Hebron Consulting physician Resident Consulting physician Consulting physician 40 41 Pharmacist Resident Resident Spain Consulting physician 78 79 Consulting physician Spain", "authors": [{"first": "J\u00falia", "middle": [], "last": "Montalv\u00e1", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Juan", "middle": [], "last": "Sellar\u00e9s-Nadal", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Nuria", "middle": [], "last": "Espinosa-Pereiro", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Fern\u00e1ndez-Hidalgo", "middle": [], "last": "", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Santiago", "middle": [], "last": "P\u00e9rez-Hoyos", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Fernando", "middle": [], "last": "Salvador", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Xavier", "middle": [], "last": "Dur\u00e0", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Marta", "middle": [], "last": "", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Andr\u00e9s", "middle": [], "last": "Miarons", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Sime\u00f3n", "middle": [], "last": "Ant\u00f3n", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Abiu", "middle": [], "last": "Eremiev-Eremiev", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Arnau", "middle": [], "last": "Sempere-Gonz\u00e1lez", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Monforte-Pallar\u00e9s", "middle": [], "last": "", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Pau", "middle": [], "last": "Bosch-Nicolau", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Salvador", "middle": [], "last": "Augustin", "suffix": "", "affiliation": {}, "email": ""}, {"first": "J\u00falia", "middle": [], "last": "Sampol", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Alfredo", "middle": [], "last": "", "suffix": "", "affiliation": {}, "email": ""}, {"first": "J\u00falia", "middle": [], "last": "Sellar\u00e9s-Nadal", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Juan", "middle": [], "last": "Espinosa-Pereiro", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Nuria", "middle": [], "last": "Fern\u00e1ndez-Hidalgo", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Marta", "middle": [], "last": "Miarons", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Andr\u00e9s", "middle": [], "last": "Ant\u00f3n", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Abiu", "middle": [], "last": "Sempere-Gonz\u00e1lez", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Arnau", "middle": [], "last": "Monforte-Pallar\u00e9s", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Alfredo", "middle": [], "last": "Guill\u00e9n-Del-Castillo", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Benito", "middle": [], "last": "Almirante", "suffix": "", "affiliation": {}, "email": ""}]}, "abstract": [{"text": "53 54 Sime\u00f3n Eremiev-Eremiev, 55 General. Enfermedades Infecciosas. 6\u00aa planta. CP 08035. Barcelona. Spain. 98 e-mail: adsanche@vhebron.net . Telephone number: +34 93 274 6090 Fax number: +34 93 99 489 40 91. 100 101 Contributions: 102 Adri\u00e1n S\u00e1nchez-Montalv\u00e1: conceptualization, database design, data curation, statistical 103 analysis, first draft writing", "cite_spans": [], "ref_spans": [], "section": "Abstract"}], "body_text": [{"text": "Results: 82 patients with COVID-19 received at least one dose of tocilizumab. The mean 151 (\u00b1 SD) age was 59.1 (19.8) years, 63% were male, 22% were of non-Spanish ancestry, and 152 the median (IQR) age-adjusted Charlson index at baseline was 3 (1-4) points. Respiratory 153 failure and ARDS developed in 62 (75.6%) and 45 (54.9%) patients, respectively. Median 154 time from symptom onset to ARDS development was 8 (5-11) days. The median time from 155 symptom onset to the first dose of tocilizumab was 9 (7-11) days. Mortality at 7 days was 156 26.8%. Hazard ratio for mortality was 3.3; 95% CI, 1.3 to 8.5 (age-adjusted hazard ratio for INTRODUCTION: 164 Coronavirus disease 2019 (COVID-19) is a novel illness caused by severe acute respiratory 165 syndrome coronavirus-2 (SARS-CoV-2). It was first reported in December 2019 in Hubei 166 province, China. 1 Since then, SARS-CoV-2 has rapidly spread worldwide. 167 According to the World Health Organization (WHO), as of April 13 th , 2020, there has been 168 1773084 laboratory-confirmed cases and 111652 deaths. 2 The case fatality rate, estimated 169 between 2.3% and 3.3%, is highly age and underlying conditions dependent. 3, 4 Death is 170 mainly due to respiratory failure caused by an acute respiratory distress syndrome (ARDS).", "cite_spans": [{"start": 641, "end": 658, "text": "INTRODUCTION: 164", "ref_id": null}, {"start": 914, "end": 917, "text": "167", "ref_id": null}, {"start": 1067, "end": 1068, "text": "2", "ref_id": null}, {"start": 1181, "end": 1183, "text": "3,", "ref_id": null}, {"start": 1184, "end": 1185, "text": "4", "ref_id": null}], "ref_spans": [], "section": ""}, {"text": "As the physiopathology behind lung injury is progressively elucidated, several therapies 172 have been proposed on the basis of pre-clinical studies and the previous experience with the 173 severe acute respiratory syndrome coronavirus-1 (SARS-CoV-1) and the Middle East In COVID-19, an excessive immune response inducing disproportionate release of cytokine 178 and hyperinflammation has been proposed as cause for the lung damage mimicking a 179 secondary haemophagocytic lymphohistiocytosis. 12 Host-directed therapies have immune-180 modulating properties with higher precision than steroids and other immune-modulating 181 therapies. 13 Tocilizumab is a humanized monoclonal antibody that inhibits interleukin-6 182 (IL-6) receptor with a well-known safety profile approved for the treatment of rheumatoid 183 arthritis and, since 2017, also approved for the treatment of chimeric antigen receptor 184 (CAR) T cell-induced severe or life-threatening cytokine release syndrome (CRS). 14,15 It 185 has been used with promising results in small retrospective cohort studies of SARS-CoV-2 186 infected patients in China. 9, 16 The efficacy of other host-directed therapies targeting 187 All rights reserved. No reuse allowed without permission.", "cite_spans": [{"start": 186, "end": 189, "text": "173", "ref_id": null}, {"start": 359, "end": 362, "text": "178", "ref_id": null}, {"start": 639, "end": 641, "text": "13", "ref_id": null}, {"start": 903, "end": 906, "text": "184", "ref_id": null}, {"start": 1115, "end": 1124, "text": "China. 9,", "ref_id": null}, {"start": 1125, "end": 1127, "text": "16", "ref_id": null}], "ref_spans": [], "section": "171"}, {"text": "(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.", "cite_spans": [], "ref_spans": [], "section": "171"}, {"text": "The copyright holder for this preprint this version posted May 12, 2020 . . https://doi.org/10.1101 /2020 hyperinflammation is being assessed under randomized clinical trial conditions for severe 188 SARS-CoV-2 infected patients. 17, 18 189 However, a proper characterization of the subset of patients who will benefit most from 190 host-directed therapies and defining the precise timing for host-directed therapies 191 administration has not yet been performed and is critical to allocate limited drug stocks and 192 reduce COVID-19 associated mortality. We aim to describe the characteristics of CoV-2 infected patients treated with tocilizumab and define poor outcome risk factors.", "cite_spans": [{"start": 59, "end": 71, "text": "May 12, 2020", "ref_id": null}, {"start": 72, "end": 99, "text": ". . https://doi.org/10.1101", "ref_id": null}, {"start": 100, "end": 105, "text": "/2020", "ref_id": null}, {"start": 230, "end": 233, "text": "17,", "ref_id": null}, {"start": 234, "end": 236, "text": "18", "ref_id": null}], "ref_spans": [], "section": "171"}, {"text": "194 All rights reserved. No reuse allowed without permission.", "cite_spans": [], "ref_spans": [], "section": "171"}, {"text": "(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. additional treatment in patients with the following criteria: 1) respiratory failure defined as 208 a ratio of arterial oxygen tension to fraction of inspired oxygen (PaO2/FiO2 ratio) of <300, 209 a ratio of arterial oxygen saturation measured by pulse oximetry to fraction of inspired 210 oxygen (SpO2/FiO2 ratio) of <315 or pO2 <60mmHg or oxygen saturation measured by 211 pulse oximetry less than 90% when breathing room air or rapidly progressive clinical 212 worsening according to treating physician and 2) interleukin-6 (IL-6) levels >40pg/mL 213 (reference 0-4.3pg/mL) or a D-dimer levels > 1500 ng/mL. Two weight bands were 214 considered for tocilizumab dosing. Patients over 75kg received 600mg, otherwise 400mg 215 was the preferred dose. A second dose was considered in patients with a poor early 216 response. Patients with liver enzymes 5 times over the upper limit of normality or 217 concomitant severe bacterial infection were not eligible for tocilizumab treatment.", "cite_spans": [], "ref_spans": [], "section": "171"}, {"text": "218 All rights reserved. No reuse allowed without permission.", "cite_spans": [], "ref_spans": [], "section": "171"}, {"text": "(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.", "cite_spans": [], "ref_spans": [], "section": "171"}, {"text": "The copyright holder for this preprint this version posted May 12, 2020 . . https://doi.org/10.1101 /2020 Data sources 219 Data were collected retrospectively from the medical charts of the patients from the 13 th of 220 March, 2020 to the 18 th of March, 2020, when the protocol was submitted to the 221 institutional review board, and prospectively thereafter. Inclusion and follow-up are still 222 ongoing. The cut-off data for inclusion in this sub-study was March 25 th , 2020. All patients 223 included were followed directly (admitted to medical or intensive care unit wards) for at 224 least 7 days. including C-reactive protein, fibrinogen, ferritin and IL-6. All radiographs were reviewed 240 by the investigators and computed tomography (CT) scans were recorded according to the 241 radiology department reports. The severity of the COVID-19 was measured with the 242 All rights reserved. No reuse allowed without permission.", "cite_spans": [{"start": 59, "end": 71, "text": "May 12, 2020", "ref_id": null}, {"start": 72, "end": 99, "text": ". . https://doi.org/10.1101", "ref_id": null}, {"start": 100, "end": 105, "text": "/2020", "ref_id": null}], "ref_spans": [], "section": "171"}, {"text": "(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The primary simple endpoint was defined as death at 7 days after first dose of tocilizumab.", "cite_spans": [], "ref_spans": [], "section": "171"}, {"text": "Secondary outcomes were admission to Intensive Care Unit (ICU), acute Respiratory 262 Distress Syndrome (ARDS) and respiratory insufficiency progression. We also assessed 263 acute myocardial infarction, septic shock, acute kidney injury and secondary infections.", "cite_spans": [], "ref_spans": [], "section": "261"}, {"text": "Berlin criteria for the ARDS were adapted, as many of the patients did not have an 265 All rights reserved. No reuse allowed without permission.", "cite_spans": [], "ref_spans": [], "section": "264"}, {"text": "(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.", "cite_spans": [], "ref_spans": [], "section": "264"}, {"text": "The copyright holder for this preprint this version posted May 12, 2020. . https://doi.org/10.1101/2020.05.07.20094599 doi: medRxiv preprint review board code number: PR(AG)183/2020). Patients were asked for an oral consent. The 290 institutional review board granted an informed consent waiver if patients were unable to 291 give oral consent. The manuscript was prepared according to the STROBE guidelines 292 recommendations. All the authors reviewed the manuscript and vouch for the accuracy and 293 completeness of the data and for the adherence of the study to the protocol. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.", "cite_spans": [{"start": 322, "end": 325, "text": "291", "ref_id": null}], "ref_spans": [], "section": "264"}, {"text": "The copyright holder for this preprint this version posted May 12, 2020. Thirty-three (40.3%) patients were former or active tobacco smokers. Coexisting conditions 313 were as follows: 32 (39.0%) had hypertension, 19 (23.5%) had lung diseases (2 (2.4%) 314 asthma, 6 (7.3%) chronic obstructive pulmonary disease among others), 17 (20.7%) had 315 obesity, 16 (19.5%) had diabetes mellitus, 11 (13.6%) had chronic kidney disease, 5 (6.1%) 316 a history of cardiac failure, 1 (1.2%) had cirrhosis. Ten (12.5%) patients were 317 immunosuppressed because of different conditions. Seventy-seven (95.1%) patients had a 318 Barthel scale index of 100 points previous to hospital admission. Table 1 shows 319 demographic and clinical characteristics at baseline. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.", "cite_spans": [], "ref_spans": [{"start": 682, "end": 689, "text": "Table 1", "ref_id": "TABREF8"}], "section": "264"}, {"text": "The copyright holder for this preprint this version posted May 12, 2020. Table 3 . 340 Oxygen supplementation and secondary outcomes. 341 Table 4 shows oxygen saturation, oxygen supplementation and ventilation support. On 342 admission, mean FiO2 oxygen supplementation was 0.36 (\u00b10.26) and mean oxygen 343 saturation was 94% (\u00b14.39). Regarding oxygen supplementation devices on admission, 34 344 (41.5%) patients were on oxygen supplementation: two (5.8%) patients were on nasal 345 cannulas, 22 (64.7%) were using face masks, 9 (26.5%) patients were using high oxygen 346 supplementation devices and 1 (2.9%) patient required endotracheal intubation with 347 mechanical ventilation. Over time, SpO2/FiO2 ratio deteriorated from a median (IQR) of 348 All rights reserved. No reuse allowed without permission.", "cite_spans": [{"start": 83, "end": 86, "text": "340", "ref_id": null}], "ref_spans": [{"start": 73, "end": 80, "text": "Table 3", "ref_id": "TABREF11"}, {"start": 138, "end": 145, "text": "Table 4", "ref_id": "TABREF12"}], "section": "264"}, {"text": "(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.", "cite_spans": [], "ref_spans": [], "section": "264"}, {"text": "The copyright holder for this preprint this version posted May 12, 2020. Table 5 . from symptom onset to tocilizumab administration was 9.0 (6.0-11.0) and from admission 368 to tocilizumab administration was 2.0 (1.0-3.0)). Other treatments include cytokine 369 hemoadsorption therapy in 2 (2.4%) patients in ICU.", "cite_spans": [], "ref_spans": [{"start": 73, "end": 80, "text": "Table 5", "ref_id": "TABREF13"}], "section": "264"}, {"text": "Main outcome and mortality risk factors 371 All rights reserved. No reuse allowed without permission.", "cite_spans": [], "ref_spans": [], "section": "370"}, {"text": "(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.", "cite_spans": [], "ref_spans": [], "section": "370"}, {"text": "The copyright holder for this preprint this version posted May 12, 2020. were hospitalized in ICU, 9 (11.0%) were hospitalized in medical wards, and 3 (3.7%) had 374 been transferred to another institution. In the univariate analysis age, age-adjusted Charlson 375 comorbidity index, medical history of active or former solid cancer, hypertension, history 376 of heart failure, chronic kidney disease and worse age-adjusted Charlson index at baseline 377 were associated with increased risk of mortality (Table 7 ). By 7-day follow-up, the 378 mortality rate was 4.0% per person-day (95% confidence interval [CI], 2.4% to 6.2%) by 379 Kaplan-Meier analysis. Mortality was more frequent in patients receiving tocilizumab once 380 ARDS was present (hazard ratio for mortality 3.3; 95% CI, 1.3 to 8.5; age-adjusted hazard 381 ratio for mortality 2.1; 95% CI, 0.8 to 5.8) (Figure 1 ) or respiratory failure was present 382 (hazard ratio for mortality 3.13; 95% CI, 1.3 to 7.8; age-adjusted hazard ratio for mortality (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.", "cite_spans": [{"start": 631, "end": 634, "text": "379", "ref_id": null}], "ref_spans": [{"start": 504, "end": 512, "text": "(Table 7", "ref_id": null}, {"start": 868, "end": 877, "text": "(Figure 1", "ref_id": null}], "section": "370"}, {"text": "The copyright holder for this preprint this version posted May 12, 2020. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.", "cite_spans": [], "ref_spans": [], "section": "370"}, {"text": "The copyright holder for this preprint this version posted May 12, 2020. . https://doi.org/10.1101/2020.05.07.20094599 doi: medRxiv preprint associated with higher mortality in the univariate analysis. Antihypertensive agents, such as (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.", "cite_spans": [], "ref_spans": [], "section": "370"}, {"text": "The copyright holder for this preprint this version posted May 12, 2020. . https://doi.org/10. 1101 /2020 As in other infections and inflammation-driven diseases, timely initiation of precise therapy 454 is the mainstay of patient management and directly affects mortality and morbidity. Our 455 study showed that patients receiving prompt treatment with tocilizumab before lung injury 456 is established have less 7-day mortality, a benefit that may be sustained in the long-term. 33", "cite_spans": [{"start": 95, "end": 99, "text": "1101", "ref_id": null}, {"start": 100, "end": 105, "text": "/2020", "ref_id": null}], "ref_spans": [], "section": "370"}, {"text": "The safety profile of tocilizumab has been extensively studied in clinical trials with patients (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.", "cite_spans": [], "ref_spans": [], "section": "457"}, {"text": "The copyright holder for this preprint this version posted May 12, 2020. . This preliminary exploratory study has several limitations. First, there is no control group 477 and the minimum follow up period was 7 days. Therefore, at this point it is not possible to 478 evaluate the differences between patients receiving tocilizumab or not and, consequently, it 479 is not possible to evaluate solidly what is the overall benefit of administering this drug. COVID-19 should consider our preliminary data in their design. All our patients were 497 treated with a combination of antiviral drugs whose efficacy is yet to be demonstrated.", "cite_spans": [], "ref_spans": [], "section": "457"}, {"text": "Host-directed therapies in the absence of antiviral drugs needs further investigation. 499 500 All rights reserved. No reuse allowed without permission.", "cite_spans": [], "ref_spans": [], "section": "498"}, {"text": "(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.", "cite_spans": [], "ref_spans": [], "section": "498"}, {"text": "The copyright holder for this preprint this version posted May 12, 2020. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.", "cite_spans": [], "ref_spans": [], "section": "498"}, {"text": "The copyright holder for this preprint this version posted May 12, 2020. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.", "cite_spans": [], "ref_spans": [], "section": "498"}, {"text": "The copyright holder for this preprint this version posted May 12, 2020. Group (ECOG) performance scale range from 0 (fully active) to 4 (completely disabled). \u222b 603", "cite_spans": [], "ref_spans": [], "section": "498"}, {"text": "The Charlson risk index score ranges from 0 to 37 with higher scores indicating a higher 604 risk of death. \u00b6 Sequential Organ Failure Assessment (SOFA) score ranges from 0 to 24 605", "cite_spans": [], "ref_spans": [], "section": "498"}, {"text": "with higher ranges indicating a higher risk or morbidity; individuals with a score of 15 or 606 more have a mortality rate of 90%. Its calculation is missing in two patients. \u00a7 Community 607 acquired pneumonia severity index assessing Confusion, Urea, Respiratory rate, Blood 608 pressure and age over 65 years (CURB-65) ranges from 0 to 5 depending on the number 609 of risk factors present in the same patient. 610 GFR: glomerular filtration rate. 611 \u00ac One patient had insterstitial lung disease and pulmonary hypertension and another 612 patient had obtructive sleep apnea syndrome and lung restrictive disease. 613 All rights reserved. No reuse allowed without permission.", "cite_spans": [], "ref_spans": [], "section": "498"}, {"text": "(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (\u00b1SD) . Rounding has been applied to percentages. Total may no be 100 because of rounding. \u2020Total number of patients varies among variables and follow up as mortality increases.", "cite_spans": [{"start": 136, "end": 141, "text": "(\u00b1SD)", "ref_id": null}], "ref_spans": [], "section": "498"}, {"text": "SpO2/FiO2 ratio: arterial oxygen saturation measured by pulse oximetry to fraction of inspired oxygen Former daily alcohol consumption -2 (9.1) All rights reserved. No reuse allowed without permission.", "cite_spans": [], "ref_spans": [], "section": "498"}, {"text": "(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.", "cite_spans": [], "ref_spans": [], "section": "498"}, {"text": "The copyright holder for this preprint this version posted May 12, 2020. Days from respiratory insufficiency to tocilizumab 0 (0 -1) 1 (0 -2) 0.055 All rights reserved. No reuse allowed without permission.", "cite_spans": [], "ref_spans": [], "section": "498"}, {"text": "(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.", "cite_spans": [], "ref_spans": [], "section": "498"}, {"text": "The copyright holder for this preprint this version posted May 12, 2020 . . https://doi.org/10.1101 /2020 administration, median (IQR) Days from ARDS to tocilizumab administration, median (IQR) 0 (-1 -0) 0 (0 -1) 0.132 *Plus-minus values are means (\u00b1SD). Rounding has been applied to percentages. Total may no be 100 because of rounding. \u2020Includes high flow oxygen delivery systems, high flow nasal cannula, non-invasive mechanical ventilation or invasive ventilation ARDS: acute respiratory distress syndrome.", "cite_spans": [{"start": 59, "end": 71, "text": "May 12, 2020", "ref_id": null}, {"start": 72, "end": 99, "text": ". . https://doi.org/10.1101", "ref_id": null}, {"start": 100, "end": 105, "text": "/2020", "ref_id": null}], "ref_spans": [], "section": "498"}, {"text": "All rights reserved. No reuse allowed without permission.", "cite_spans": [], "ref_spans": [], "section": "498"}, {"text": "(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.", "cite_spans": [], "ref_spans": [], "section": "498"}, {"text": "The copyright holder for this preprint this version posted May 12, 2020 . . https://doi.org/10.1101 /2020 ", "cite_spans": [{"start": 59, "end": 71, "text": "May 12, 2020", "ref_id": null}, {"start": 72, "end": 99, "text": ". . https://doi.org/10.1101", "ref_id": null}, {"start": 100, "end": 105, "text": "/2020", "ref_id": null}], "ref_spans": [], "section": "498"}], "bib_entries": {"BIBREF0": {"ref_id": "b0", "title": "Prothrombin time", "authors": [], "year": null, "venue": "", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF1": {"ref_id": "b1", "title": "Urea, median (IQR) -mg/dl 43", "authors": [], "year": null, "venue": "", "volume": "", "issn": "", "pages": "38--72", "other_ids": {}}, "BIBREF2": {"ref_id": "b2", "title": "Glomerular filtrate, mean -CKD-EPI", "authors": [], "year": null, "venue": "", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF3": {"ref_id": "b3", "title": "Aspartate aminotransferase > 40 U/litre 42 (53.9%) 25 (61%) 30 (66.7%)", "authors": [], "year": null, "venue": "", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF4": {"ref_id": "b4", "title": "Alanine aminotransferase", "authors": [], "year": null, "venue": "", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF5": {"ref_id": "b5", "title": "Alanine aminotransferase > 40 U/litre 28", "authors": [], "year": null, "venue": "", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF6": {"ref_id": "b6", "title": "Alkaline phosphatase", "authors": [], "year": null, "venue": "", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF7": {"ref_id": "b7", "title": "Gamma-glutamyl transferase, mean", "authors": [], "year": null, "venue": "", "volume": "", "issn": "", "pages": "", "other_ids": {}}}, "ref_entries": {"FIGREF0": {"text": "Modulation of the immune system to prevent lung injury is being widely 142 used against the new coronavirus disease (COVID-19) despite the scarcity of evidence. 143 Methods: We report preliminary results from the Vall d'Hebron prospective cohort study 144 at Vall d'Hebron University Hospital, in Barcelona (Spain), including all consecutive 145 patients who had a confirmed infection with the severe acute respiratory syndrome 146 coronavirus-2 (SARS-CoV-2) and who were treated with tocilizumab until March 25 th . The 147 primary endpoint was mortality at 7 days after tocilizumab administration. Secondary 148 endpoints were admission to the intensive care unit, development of ARDS and respiratory 149 insufficiency among others.", "latex": null, "type": "figure"}, "FIGREF2": {"text": "Syndrome Coronavirus (MERS-CoV). 5,6 Many of them are being used off label 175 in a desperate attempt to improve patient outcomes, including antiviral therapies, 176 coagulation modifying drugs and immune-modulating therapies. 7-11 177", "latex": null, "type": "figure"}, "FIGREF3": {"text": "Laboratory-confirmed case was defined as a patient with a real-time reverse-transcriptase-226 polymerase-chain-reaction (RT-PCR) SARS-CoV-2 positive result in any respiratory 227 sample (nasopharyngeal swab, sputum, bronchoalveolar lavage or aspirate, tracheal 228 aspirate", "latex": null, "type": "figure"}, "FIGREF4": {"text": "the onset of the outbreak until 15 th of March the microbiological diagnosis was based 247 on a homebrew RT-PCR assay targeting two viral targets (N1 and N2) into viral 248 nucleocapsid (N) gene and one into envelope (E) gene of SARS-CoV-2, as well as the 249 human RNase P (RP) gene as an internal control of the whole process, according to the 250 CDC and ECDC Real-Time RT-PCR Diagnostic Panels with minor modifications. 21 Since 251 March 15 th , commercial Allplex\u2122 2019-nCoV multiplex RT-PCR (Seegene, South Korea) 252 were used for the detection of three viral targets (E; N; and, RNA-dependent RNA 253 polymerase, RdRp) and an internal control. First SARS-CoV-2 laboratory-confirmations 254 were confirmed by RdRp sequencing. 22,23 Total nucleic acids (DNA/RNA) were extracted 255 from respiratory specimens using NucliSENS easyMAG (BioMerieux, France) 256 and STARMag Universal Cartridge Kit (Seegene, South Korea) according to the 257 manufacturer's instructions. All microbiological procedures were carried out in the", "latex": null, "type": "figure"}, "FIGREF5": {"text": "Mortality in the cohort was described with the use of Kaplan-Meier analysis. Tests were 277 considered significant when the two-tailed p-value was <0.05. We did not correct for278 multiple comparisons; hence, the widths of the confidence intervals should not be 279 interpreted as definitive for the associations with the outcomes. Association between time 280 to tocilizumab administration and mortality were assessed by means of Cox proportional 281 hazards regression. Missing urea and bilirubin levels on admission were assumed normal 282 for CURB-65 and SOFA calculation; no other imputation was made for missing data.", "latex": null, "type": "figure"}, "FIGREF6": {"text": "Analysis was performed with Stata 15.1 software (StataCorp).", "latex": null, "type": "figure"}, "FIGREF7": {"text": "was designed and conducted by the investigators from the Vall d'Hebron 287 COVID-19 Prospective Cohort Study. Data were collected, debugged, analysed and 288 interpreted by the authors. The institutional review board provided ethical clearance (local 289 All rights reserved. No reuse allowed without permission.", "latex": null, "type": "figure"}, "FIGREF8": {"text": "the current emergency of the SARS-CoV-2 pandemic, patients were not involved in 297 the design and the conduct of the study, including the selection of the outcomes and", "latex": null, "type": "figure"}, "FIGREF9": {"text": "onset of the COVID-19 outbreak until March 25 th , 3242 respiratory-derived 303 samples have been requested from our institution for COVID-19 diagnosis. Samples were 304 requested from the emergency room and hospitalization wards, as well as from the health 305 care worker surveillance strategy plan. From them, 941 were positive (29%). During this 306 period, 82 SARS-CoV-2 infected patients received at least one dose of tocilizumab. The 307 mean (\u00b1SD) age was 59.1 (\u00b119.8) years (95% Confidence Interval 54.8-63.5). Fifty-two 308 patients were male (63.5%). Eighteen (21.9%) patients were born abroad, 13 (16.1%) in 309 Latin America, 3 (3.7%) in Eastern Europe and 2 (2.4%) in North Africa. The mean (\u00b1SD) 310 duration of symptoms before hospital admission was 6.7 (\u00b14.4) days. Fever and cough were 311 the main symptoms on admission, occurring in 75 (91.5%) and 71 (86.6%) respectively.", "latex": null, "type": "figure"}, "FIGREF11": {"text": "admission, mean (\u00b1SD) white cell count was 9.2 (10.4) with 17 (21.3%) patients having 322 more than 10000 per cubic millilitre white cells. Lymphocytopenia (<1000 cells per cubic 323 millilitre) was present in 46 (57.5%) patients. Interleukin-6 median (IQR) plasma level on 324 All rights reserved. No reuse allowed without permission.", "latex": null, "type": "figure"}, "FIGREF12": {"text": "patients had a positive RT-PCR for SARS-CoV-2 in a respiratory-derived 330 sample. On admission, 2 patients out of 56 had a positive pneumococcal urinary antigen 331 result. Sputum samples from 13 patients were sent on admission, bacterial growth was 332 demonstrated in 3 samples, two with Haemophilus influenzae that were considered 333 clinically significant and one was deemed contamination with oral bacteria. During the first 334 7 days follow up, 2 more positive results were retrieved: one Extended-Spectrum Beta-335 Lactamase (ESBL)-producing Escherichia coli (considered clinically significant) and one 336 Staphylococcus epidermidis (considered non-clinically significant). Blood samples from 65 337 patients were sent, and one positive bacterial growth (coagulase-negative Staphylococcus) 338 was observed, although considered a contamination. Detailed microbiologic data are shown 339 in", "latex": null, "type": "figure"}, "FIGREF13": {"text": "350 therapy, including high flow oxygen delivery systems, high flow nasal cannula, non-351 invasive mechanical ventilation or invasive ventilation during the study period. Median 352 (IQR) days on high flow oxygen delivery systems, high flow nasal cannula, non-invasive 353 mechanical ventilation or invasive ventilation before progression to other intensive oxygen 354 therapy, outcome attainment or data censoring were 2.respectively. The median (IQR) days from admission to first intensive 356 oxygen therapy was 2.0 (1.0-4.5). Only one (1.2%) patient required vasopressor therapy 357 due to hypotension. No patient required renal replacement therapy. Respiratory failure and 358 ARDS developed in 62 (75.6%) and 45 (54.9%) patients, respectively. Median (IQR) days 359from symptoms to respiratory failure and ARDS were 8 respectively. Secondary outcomes can be found in", "latex": null, "type": "figure"}, "FIGREF14": {"text": "one (98.9%) patients received hydroxychloroquine, 63 (76.8%) lopinavir/ritonavir, 364 21 (25.61%) darunavir/cobicistat, and 79 (96.34%) azithromycin. All patients were initially 365 treated with antibiotic therapy, mainly ceftriaxone (77 (93.9%) patients). As expressed 366 before, all patients received at least one dose of tocilizumab. Median (IQR) time in days 367", "latex": null, "type": "figure"}, "FIGREF15": {"text": "2). When dividing patients according to the nearest 384 SpO2/FiO2 ratio to tocilizumab administration, mortality was higher among patients with 385 lower SpO2/FiO2 ratio (SpO2/FiO2 ratio<200, 46.2%; SpO2/FiO2 ratio 200-300, 16.7%; 386 SpO2/FiO2 ratio >300, 20.6%; p=0.03)(Figure 3). Distribution of the nearest SpO2/FiO2 387 ratio to tocilizumab administration depending on outcome groups was not statistically 388 significant (mean (SD) SpO2/FiO2 ratio: 321.3 (154.7) dead, 343.1 (132.7) ICU, 396.9 389 (96.2) alive; p=0.2)(Figure 4). No correlation was observed between nearest IL-6 levels to 390 tocilizumab administration and main outcome (median (IQR) IL-6 levels: 79.7 (48.2-128.1) 391 dead, 77.5 (55-120) ICU admission, 71.4 (49.4-116) alive; p=0.92). Basal characteristics of 392 patients stratified by ARDS and respiratory failure can be found in", "latex": null, "type": "figure"}, "FIGREF16": {"text": "characteristics and clinical outcomes of patients who were hospitalized in 408 non-ICU wards and received treatment with tocilizumab. Our results show that a timely 409 administration of immune-modulating therapies, before the onset of respiratory 410 insufficiency or ARDS, can improve severe COVID-19 patients' outcomes with a three-411 fold reduction in 7-day mortality. 412 Therapies to improve outcomes of patients with COVID-19 focus on viral-directed 413 therapies and host-directed therapies. There is still lack of evidence about the efficacy of 414 any of these therapies, although this does not prevent physicians to use all sort of off-label 415 therapies despite the risk of serious adverse events. 26 Therapies to curb uncontrolled 416 cytokine release have been proposed and are being widely used. Randomized controlled 417 trials with host-directed therapies are currently under way and results will be available 418 within the next months. 17,18 Meanwhile, data from prospective studies can help to improve 419 COVID-19 patients management. In our study, the 7-day mortality was 26.8%, slightly 420 higher than a recent experience with remdesivir and similar to the mortality of 22.1% 421 reported in another study with lopinavir/ritonavir. 27,28 However, the patients in our 422 prospective cohort had more coexisting conditions, including potential mortality risk 423 factors such as hypertension, other cardiovascular and metabolic diseases, chronic kidney 424 disease and cancer. 425 The understanding of mortality risk factors in patients with COVID-19 is an evolving 426 matter. Age, specific coexisting conditions and laboratory parameters may help identifying 427 patients with poor outcome. 29 As expressed before, in our cohort of patients treated with 428 tocilizumab, hypertension, history of cardiac failure and chronic kidney disease were 429 All rights reserved. No reuse allowed without permission.", "latex": null, "type": "figure"}, "FIGREF17": {"text": "ARB), have been suggested to be associated with the increase mortality observed in this 432 subset of patients. Angiotensin converting enzyme 2 plays an important role in SARS-CoV-433 2 viral entry as co-receptor. 30 Hypothesis outline that the interactions between these drugs 434 and co-receptors may increase viral spreading in the lung and pose the patients at a higher 435 risk of death. However, the evidence is limited and no specific recommendations could be 436 drawn from current evidence, especially when ACEI and ARB have shown to reduce 437 mortality in this at risk population. 31 The Vall d'Hebron COVID-19 Prospective Cohort 438 Study has among its main objectives to analyse the role of these and other drugs used to 439 treat chronic conditions in the prognosis of patients with COVID-19.", "latex": null, "type": "figure"}, "FIGREF18": {"text": "Host-directed therapies aiming at blocking an unrestrained immune response and an441 excessive inflammation have been proposed as potential therapies to prevent acute lung 442 injury and subsequent ARDS. SARS-CoV-2 infection severity has been associated with an 443 increase in IL-6 and D dimer levels, and the cytokine profile resembles that of other 444 conditions in which host-directed therapies have been successfully used. 13,29,32 Timely use 445 of host-directed therapies may curb uncontrolled cytokine release and prevent damage 446 inflicted by hyperinflammation. Tocilizumab has shown to be safe in two small Chinese 447 cohort studies of patients with COVID-19. 9,16 Efficacy of tocilizumab, measured as hospital 448 discharge, was 90.5% (19 out of 21 patients) in patients with COVID-19 needing oxygen 449 supplementation and having elevated IL-6 in one study 9 ; while the other study showed 3 450 deaths, 10 clinical stabilizations and 2 clinical aggravation out of 15 patients. 16 Other 451 laboratory and radiologic findings also improved in a short period of time. However, 452 standard of care in the studies was different limiting the possibility of direct comparisons.", "latex": null, "type": "figure"}, "FIGREF20": {"text": "458 suffering autoimmune diseases. The most common adverse events of intravenous 459 tocilizumab in a pooled analysis of 3 clinical trials were upper respiratory infections, 460 nasopharyngitis, headache, hypertension and increase in liver enzymes. Serious adverse 461 events occurred in 12% of the patients, being infectious diseases the most common. 34 In our 462 study we did not report any serious adverse event, although the symptoms of systemic viral 463 infections may mimic any adverse event and difficult its identification. Tozilizumab-related 464 bacterial infections were not reported in our study. Two factors may have contributed to 465 this: first, many patients were under antibiotic treatment, and second, the short follow up 466 period precludes us from any further analysis. Nevertheless, the low cumulative dose 467 administered in this subset of patients may diminish the likelihood of infectious adverse 468 events. 469 In a time of scarce medical resources, including limited stock of host-directed therapies, 470 hard medical decisions have to be done by first-line physicians. Allocation of therapies to 471 patients with the highest chances of a favourable outcome should be encouraged, 472 maximizing the benefit of the intervention. 35 Evidence-based decision-making and benefit-473 maximizing allocation of the available resources should be promoted. In this regards our 474 study can help physicians to better allocate host-directed therapy in patients with COVID-47519 prioritizing moderate-to-severe ill patients over critically ill patients.", "latex": null, "type": "figure"}, "FIGREF22": {"text": "However, the urgency of obtaining data on new therapies justifies the early communication481 of these results. Second, ICU admission is not a very robust endpoint since it depends on 482 the attitudes of the treating physicians as well as the availability of beds at times of resource 483 scarcity and overwhelming demand. For this reason, mortality was selected as the main 484 outcome in our study. Besides, the subsequent analysis of all patients included in the Vall 485 d'Hebron COVID-19 Prospective Cohort Study may solve this limitation and inform results 486 with a longer follow up period. Finally, our data is limited to a single centre. While our 487 results may not be extrapolated to other populations or other standards of care, the 488 management of patients was homogeneous avoiding the centre effect of multicentric 489 studies. Multivariate analysis is limited by sample size. 490 In summary, we found a mortality rate of 26.8% in this subset of patients with COVID-19 491 receiving tocilizumab for the treatment of inflammatory-related lung injury. Time from 492 lung injury onset to tocilizumab administration may be critical to patient recovery. Our 493 results may help front line physician to make evidence-based decisions in times of scarce 494 resources and operationalized fair and transparent allocation procedures, maximizing the 495 benefit of the intervention. Future and current host-directed clinical trials for patients with 496", "latex": null, "type": "figure"}, "FIGREF23": {"text": "C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel 503 coronavirus in Wuhan, China. Lancet Lond Engl 2020;395(10223):497-506. 504 2. Novel Coronavirus (2019-nCoV) situation reports [Internet]. [cited 2020 Apr 505 1];Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-", "latex": null, "type": "figure"}, "FIGREF24": {"text": "Hauser A, Counotte MJ, Margossian CC, et al. Estimation of SARS-CoV-2 mortality 512 during the early stages of an epidemic: a modelling study in Hubei, China and 513 northern Italy. medRxiv 2020;2020.03.04.20031104. 514 5. De Clercq E. Potential antivirals and antiviral strategies against SARS coronavirus 515 infections. Expert Rev Anti Infect Ther 2006;4(2):291-302. 516 6. Al-Tawfiq JA, Memish ZA. Update on therapeutic options for Middle East 517 Respiratory Syndrome Coronavirus (MERS-CoV). P, Lagier J-C, Parola P, et al. Hydroxychloroquine and azithromycin as a 520 treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J 521 Antimicrob Agents 2020;105949. 522 8. Chen Z, Hu J, Zhang Z, et al. Efficacy of hydroxychloroquine in patients with 523 COVID-19: results of a randomized clinical trial. medRxiv 524 2020;2020.03.22.20040758. 525 9. Xu X, Han M, Li T, et al. Effective treatment of severe COVID-19 patients with 526 tocilizumab. Available from: chinaXiv:202003.00026v1 (2020). 527 www.chinaxiv.org/abs/202003.00026 528 10. Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated 529 with decreased mortality in severe coronavirus disease 2019 patients with 530 coagulopathy. J Thromb Haemost JTH 2020; 531 11. Richardson P, Griffin I, Tucker C, et al. Baricitinib as potential treatment for 2019-532 nCoV acute respiratory disease. Lancet Lond Engl 2020;395(10223):e30-1.", "latex": null, "type": "figure"}, "FIGREF26": {"text": "Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With 547 COVID-19 -Full Text View -ClinicalTrials.gov [Internet]. [cited 2020 Apr 548 11];Available from: https://clinicaltrials.gov/ct2/show/NCT04315298 549 18. Study of the Efficacy and Safety of Ruxolitinib to Treat COVID-19 Pneumonia -Full 550 Text View -ClinicalTrials.gov [Internet]. [cited 2020 Apr 11];Available from: 551 https://clinicaltrials.gov/ct2/show/NCT04331665 552 19. Lim WS, van der Eerden MM, Laing R, et al. Defining community acquired 553 pneumonia severity on presentation to hospital: an international derivation and 554 validation study. Thorax 2003;58(5):377-82.555 20. Seymour CW, Liu VX, Iwashyna TJ, et al. Assessment of Clinical Criteria for Sepsis. 556 JAMA 2016;315(8):762-74. 557 21. World Health Organization. Laboratory testing for 2019 novel coronavirus (2019-558 nCoV) in suspected human cases. WHO -Interim Guid 2020;2019(January):1-7. 559 22. Mo\u00ebs E, Vijgen L, Keyaerts E, et al. A novel pancoronavirus RT-PCR assay: frequent 560 detection of human coronavirus NL63 in children hospitalized with respiratory tract 561 infections in Belgium. BMC Infect Dis 2005;5:6. 562 23. Woo PCY, Lau SKP, Lam CSF, et al. Discovery of a novel bottlenose dolphin 563 coronavirus reveals a distinct species of marine mammal", "latex": null, "type": "figure"}, "FIGREF28": {"text": "Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult 577 inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 578 Lond Engl 2020;395(10229):1054-62. 579 30. Zhou P, Yang X-L, Wang X-G, et al. A pneumonia outbreak associated with a new 580 coronavirus of probable bat origin. Nature 2020;579(7798):270-3. 581 31. Patel AB, Verma A. COVID-19 and Angiotensin-Converting Enzyme Inhibitors and 582 Angiotensin Receptor Blockers: What Is the Evidence? JAMA 2020; 583 32. Lee DW, Gardner R, Porter DL, et al. Current concepts in the diagnosis and 584 management of cytokine release syndrome. Blood 2014;124(2):188-95. 585 33. Ngai JC, Ko FW, Ng SS, To K-W, Tong M, Hui DS. The long-term impact of severe 586 acute respiratory syndrome on pulmonary function, exercise capacity and health 587 status. Respirol Carlton Vic 2010;15(3):543-50. 588 34. Nishimoto N, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Azuma J. Long-term 589 safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in 590 monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of 591 safety and efficacy in a 5-year extension study. Ann Rheum Dis 2009;68(10):1580-4. 592 35. Emanuel EJ, Persad G, Upshur R, et al. Fair Allocation of Scarce Medical Resources 593 in the Time of Covid-19. N Engl J Med 2020; 594 TABLES 597", "latex": null, "type": "figure"}, "TABREF0": {"text": "Study setting and populationThe Vall d'Hebron COVID-19 Prospective Cohort Study includes all consecutive adult patients (\u2265 18 years old) diagnosed with COVID-19 at Vall d'Hebron University Hospital, 198 a 1100-beds public tertiary care hospital in Barcelona, Spain. For this study we selected the 199 subgroup of patients with laboratory-confirmed COVID-19 and radiologically confirmed pneumonia who received at least one dose of tocilizumab. Identification and inclusion of patients receiving tocilizumab was assured from the Pharmacy Department registry.Standard of care and tocilizumab administration criteriaAt admission, all patients were initially evaluated with chest radiography and blood test 204 including cell count, coagulation study, biochemistry and inflammatory parameters.Treatment with lopinavir/ritonavir, azithromycin and hydroxychloroquine was initiated according to Vall d'Hebron University Hospital protocol. Tocilizumab was considered as", "latex": null, "type": "table"}, "TABREF1": {"text": ").We collected sociodemographic characteristics, past medical history, Charlson comorbidity score, concomitant medication, current therapy, adverse drug events (graded according to the Common Terminology Criteria for Adverse Events, CTCAE, version 5), blood test results, imaging studies, microbiological tests other than SARS-CoV-2 RT-PCR on respiratory samples when available, and supportive measures needed. Vital signs, symptoms and physical examination were evaluated on admission, at 48h and weekly during hospital admission. Laboratory, microbiology and imaging studies were performed on admission and thereafter according to the clinical care needs of each patient. Laboratory assessments consisted of a complete blood count, coagulation testing including D-dimer measurement, liver and renal function, electrolyte profile, and inflammatory profile", "latex": null, "type": "table"}, "TABREF2": {"text": "CURB-65 scale for community acquired pneumonia and other scales.19,20  Data was recorded in the Research Electronic Data Capture software (REDCap, Vanderbilt", "latex": null, "type": "table"}, "TABREF3": {"text": "available arterial O2 pressure due to the overwhelming volume of admitted patients that precluded us from performing arterial blood samples to all patients. Instead, we used oxygen saturation by pulse oximetry and its correlation to the inspired fraction of oxygen Continuous variables are expressed as mean and standard deviation or medians and interquartile range, as appropriate. Categorical variables were summarized as absolute number and percentages. Comparisons among groups was performed with Chi squared test and Fisher's test for categorical variables; and Student's T test and Mann-Whitney U test for continuous variables. Box plots and bar plots are also provided for some associations.", "latex": null, "type": "table"}, "TABREF4": {"text": ". https://doi.org/10.1101/2020.05.07.20094599 doi: medRxiv preprint 428 (316.1-454.8) on admission, 271.4 (158.3-361.5) at 48 hours and 230.2 (118.8-346.4) at 7 days follow up (p<0.001). Fifty-five (69.6%) patients required intensive oxygen", "latex": null, "type": "table"}, "TABREF6": {"text": "summarizes main outcome in the study population. At the end of the follow up period, of the 82 patients 34 (41.5%) had been discharged, 22 (26.8%) had died, 14 (17.1%)", "latex": null, "type": "table"}, "TABREF7": {"text": "Twelve (14.63%) out of 82 patients reported a total of 14 adverse events during the follow up. Thirteen (92.9%) adverse events were considered related with lopinavir/ritonavir, 9 (75.0%) patients discontinued lopinavir/ritonavir treatment due to gastrointestinal symptoms. Diarrhoea was the most common reported adverse event. Other adverse events included nausea and dysuria. There were no adverse events attributed to tocilizumab. No serious adverse events were reported during follow up, and only 2 (14.3%) were considered moderate. Eleven (91.7%) patients recovered without medical sequelae and one patient had an unknown outcome. No tocilizumab discontinuation was reported due to adverse events.All rights reserved. No reuse allowed without permission.", "latex": null, "type": "table"}, "TABREF8": {"text": "Demographic and clinical characteristics of the patients at baseline* 598", "latex": null, "type": "table", "html": "<html><body><table><tr><td>Characteristics </td><td>Patients (n=82) </td></tr><tr><td>Age, mean - yr </td><td> 59.1 \u00b119.8 </td></tr><tr><td>Sex - no (%) </td><td>\u00a0</td></tr><tr><td>Male </td><td> 52 (63.4%) </td></tr><tr><td>Female </td><td> 30 (36.6%) </td></tr><tr><td>Origin </td><td>\u00a0</td></tr><tr><td>Spain </td><td> 63 (77.8%) </td></tr><tr><td>Latin America </td><td> 13 (16.1%) </td></tr><tr><td>East Europe </td><td> 3 (3.7%) </td></tr><tr><td>North Africa (Magreb) </td><td>2 (2.4%) </td></tr><tr><td>Coexisting condition - no (%) Active tabacco smoker </td><td>5 (6.1%) </td></tr><tr><td>Former tabacco smoker </td><td>28 (34.2%) </td></tr><tr><td>Never smoke </td><td>49 (59.8%) </td></tr><tr><td>Active daily alcohol consumption </td><td>1 (1.2%) </td></tr><tr><td>Former daily alcohol consumption </td><td>2 (2.4%) </td></tr><tr><td>Never drink daily </td><td>79 (96.3%) </td></tr><tr><td>Cognitive imparment </td><td>1 (1.2%) </td></tr><tr><td>Diabetes Mellitus </td><td>16 (19.5%) </td></tr><tr><td>Immunosuppression </td><td>10 (12.2%) </td></tr><tr><td>Solid organ transplant </td><td>5 (6.1%) </td></tr><tr><td>Drug induced immunosuppression </td><td>3 (3.7%) </td></tr><tr><td>Bone marrow transplant </td><td>1 (1.2%) </td></tr><tr><td>Other </td><td>1 (1.2%) </td></tr><tr><td>Former cancer (includes any solid cancer) Active cancer (includes any solid cancer) </td><td>9 (11.1%) 2 (2.4%) </td></tr><tr><td>Former haematological condition (includes </td><td>3 (3.7%) </td></tr><tr><td>leukemia and lymphoma) Active haematological condition (includes leukemia and lymphoma) </td><td>2 (2.4%) </td></tr><tr><td>\u00a0</td></tr><tr><td>Hypertension </td><td>32 (39%) </td></tr><tr><td>Hystory of cardiac failure </td><td>5 (6.1%) </td></tr><tr><td>Atrial fibrillation </td><td>10 (12.2%) </td></tr><tr><td>Lung diseases \u00ac </td><td>19 (23.5%) </td></tr><tr><td>Chronic obstructive pulmonary disease </td><td>6 (7.3%) </td></tr><tr><td>Obstructive sleep apnea syndrome </td><td>3 (3.7%) </td></tr><tr><td>Insterstitial lung disease </td><td>2 (2.4%) </td></tr><tr><td>Asthma </td><td>2 (2.4%) </td></tr><tr><td>Bronchiectasis </td><td>2 (2.4%) </td></tr><tr><td>Lung restritive disease </td><td>2 (2.4%) </td></tr><tr><td>Lung transplant </td><td>2 (2.4%) </td></tr><tr><td>Pulmonary hypertension </td><td>1 (2.4%) </td></tr><tr><td>Controlled pulmonary tuberculosis </td><td>1 (2.4%) </td></tr><tr><td>Chronic kidney disease </td><td>11 (13.6%) </td></tr><tr><td>GFR&gt;50 </td><td>3 (27.3%) </td></tr></table></body></html>"}, "TABREF9": {"text": "The copyright holder for this preprint this version posted May 12, 2020. . https://doi.org/10.1101org/10. /2020", "latex": null, "type": "table"}, "TABREF10": {"text": "Status on admission and follow up* *Plus-minus values are means (\u00b1SD). Rounding has been applied to percentages. Total may no be 100 because of rounding. \u2020Total number of patients varies among variables and follow up as mortality increases. \u2021Some patients have more than one radiologic abnormality.", "latex": null, "type": "table"}, "TABREF11": {"text": "Laboratory data at admission and follow up* Plus-minus values are means (\u00b1SD). Rounding has been applied to percentages. Total may no be 100 because of rounding. \u2020Total number of patients varies among variables and follow up as mortality increases.", "latex": null, "type": "table"}, "TABREF12": {"text": "Oxygen supplementation and supportive ventilation on admission and follow up* Plus-minus values are means", "latex": null, "type": "table"}, "TABREF13": {"text": "Secondary outcomes at 7-day follow up from tocilizumab administration.Table 6. Main outcome at 7-day follow up from tocilizumab administration.Table 7. Comparison of risk factors by in-hospital mortality.", "latex": null, "type": "table"}, "TABREF14": {"text": ". https://doi.org/10.1101/2020.05.07.20094599 doi: medRxiv preprint", "latex": null, "type": "table"}}, "back_matter": []}